Global Research Trends on the Treatment of Diffuse Large B-Cell Lymphoma: A Bibliometric and Visualized Study

被引:4
作者
Duan, Qintong [1 ]
Li, Yufeng [1 ]
Ou, Lijia [1 ]
Li, Yajun [2 ]
Zeng, Ruolan [2 ]
He, Yizi [2 ]
Pan, Tao [2 ]
Chen, Siwei [1 ]
Chen, Huan [3 ]
Zang, Hui [4 ]
Zhou, Hui [2 ]
Xiao, Ling [1 ]
机构
[1] Cent South Univ, Dept Histol & Embryol, Sch Basic Med Sci, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Dept Lymphoma & Hematol, Changsha, Hunan, Peoples R China
[3] Hunan Univ Med, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Huaihua 418000, Peoples R China
[4] Yiyang Med Coll, Dept Human Anat & Histoembryol, Sch Basic Med Sci, Yiyang, Peoples R China
来源
JOURNAL OF CANCER | 2022年 / 13卷 / 05期
基金
中国国家自然科学基金;
关键词
Key words; diffuse large B-cell Lymphoma (DLBCL); treatment; research progress; bibliometric analysis; Visualized; VOSviewer; PUBLIC-HEALTH RESEARCH; R-CHOP; PHASE-III; FRONTLINE RITUXIMAB; INFECTIOUS-DISEASES; SALVAGE REGIMENS; TRANSPLANTATION; LENALIDOMIDE; TRIAL; CYCLOPHOSPHAMIDE;
D O I
10.7150/jca.68453
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Treatment of DLBCL has improved greatly in recent decades, with thousands of papers published. We conducted a bibliometric analysis of the literature on DLBCL treatment, and discussed cooperation among authors, countries, and institutions, and identified research hotspots for DLBCL treatment. We searched the Web of Science Core Collection (WOSCC) using "Diffuse Large B Cell Lymphoma or DLBCL" and "Treatment or Therapy or Clinical Trial" as the subject terms, and analyzed the publication year, research direction, country/region, institution, author, source publication, distribution of funding institutions, and other conditions provided by the database. In addition, scientometrics software was used to analyze literature citations and cooperative publications. Bibliometric analyses were performed using https://bibliometric.com/app and VOSviewer. Network maps were generated to evaluate collaborations between different authors, countries, institutions, and keywords. A total of 7,255 studies on treatment of DLBCL were retrieved from the WOSCC on February 19, 2021. We found that the number of publications increased gradually from 1999 to 2021, and this trend was relatively stable in the past 3 years. The countries that produced the most publications were the United States, China, and Japan. Among institutions, University of Texas MD Anderson Cancer Center published the most manuscripts. Furthermore, the United States also had the most annual publications, citations, distribution of journal sources, and funding. Cooperative research between countries is also relatively important to treatment of DLBCL. Therapeutic regimens such as CHOP and R-CHOP, and immunotherapy (CAR-T, PD1/PDL1, and CAR-NK, etc.), have received increased attention. Bibliometric analysis of studies related to DLBCL treatment can help researchers and clinical workers quickly understand the hotspots and development trends in this field, and provide reference for the formulation of public health policies.
引用
收藏
页码:1785 / 1795
页数:11
相关论文
共 50 条
  • [31] Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
    Melani, Christopher
    Lakhotia, Rahul
    Pittaluga, Stefania
    Phelan, James D.
    Huang, Da Wei
    Wright, George
    Simard, Jillian
    Muppidi, Jagan
    Thomas, Craig J.
    Ceribelli, Michele
    Tosto, Frances A.
    Yang, Yandan
    Xu, Weihong
    Davies-Hill, Theresa
    Pack, Svetlana D.
    Peer, Cody J.
    Arisa, Oluwatobi
    Mena, Esther
    Lindenberg, Liza
    Bergvall, Ethan
    Portell, Craig A.
    Farah, Rafic J.
    Lee, Seung Tae
    Pradhan, Amynah
    Morrison, Candis
    Tadese, Atekelt
    Juanitez, Anna Marie
    Lu, Crystal
    Jacob, Allison
    Simmons, Heidi
    Figg, William D.
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Roschewski, Mark
    Staudt, Louis M.
    Wilson, Wyndham H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (23) : 2143 - 2155
  • [32] An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma
    Walji, Moneeza
    Assouline, Sarit
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (09) : 933 - 942
  • [33] Nomogram for predicting survival of patients with diffuse large B-cell lymphoma
    Fujii, Keiichiro
    Inagaki, Atsushi
    Masaki, Ayako
    Sugiura, Mariko
    Suzuki, Tomotaka
    Ishida, Takashi
    Kusumoto, Shigeru
    Iida, Shinsuke
    Inagaki, Hiroshi
    ANNALS OF HEMATOLOGY, 2024, 103 (06) : 2041 - 2050
  • [34] The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma
    Phipps, Colin
    Lee, Yuh Shan
    Ying, Hao
    Nagarajan, Chandramouli
    Grigoropoulos, Nicholas
    Chen, Yunxin
    Tang, Tiffany
    Goh, Alan Z.
    Ghosh, Aditi
    Ng, Heng Joo
    Gopalakrishnan, Sathish
    Loh, Yvonne
    Lim, Soon Thye
    Hwang, William
    Tan, Daryl
    Goh, Yeow Tee
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2336 - 2341
  • [35] Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma
    Shen, Rong
    Fu, Di
    Dong, Lei
    Zhang, Mu-Chen
    Shi, Qing
    Shi, Zi-Yang
    Cheng, Shu
    Wang, Li
    Xu, Peng-Peng
    Zhao, Wei-Li
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [36] Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, M.
    Sharman, Jeff P.
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yuqin
    Greil, Richard
    Mykhalska, Larysa
    Bergua-Burgues, Juan M.
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Abrisqueta, Pau
    Gau, Jyh-Pyng
    Hirata, Jamie
    Jiang, Yanwen
    Yan, Mark
    Lee, Calvin
    Flowers, Christopher R.
    Salles, Gilles
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04) : 351 - 363
  • [37] New treatment options in elderly patients with Diffuse Large B-cell Lymphoma
    Arcari, Annalisa
    Cavallo, Federica
    Puccini, Benedetta
    Vallisa, Daniele
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [38] Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Harris, Leonard Jeff
    Patel, Kruti
    Martin, Michael
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 12
  • [39] Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma Genetic Classification and Its Implications for Prognosis and Treatment
    Crombie, Jennifer L.
    Armand, Philippe
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2019, 33 (04) : 575 - +
  • [40] Diffuse large B-cell lymphoma in the older
    Gutierrez, A.
    Mestre, F.
    Perez-Manga, G.
    Rodriguez, J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (01) : 59 - 72